Cyclo Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Cyclo Therapeutics wird ein Gewinn- und Umsatzwachstum von 54.3% bzw. 66.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 59.9% pro Jahr wachsen soll.

Wichtige Informationen

42.2%

Wachstumsrate der Gewinne

53.2%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	71.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	27 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Aug 16

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

Jul 12

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Apr 27

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:CYTH - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	15	-22	N/A	N/A	2
12/31/2025	1	-27	-24	-24	3
12/31/2024	1	-22	-22	-22	3
6/30/2024	1	-21	-18	-18	N/A
3/31/2024	1	-19	-18	-18	N/A
12/31/2023	1	-20	-16	-16	N/A
9/30/2023	1	-19	-15	-15	N/A
6/30/2023	1	-19	-14	-14	N/A
3/31/2023	1	-18	-15	-15	N/A
12/31/2022	1	-15	-15	-15	N/A
9/30/2022	2	-13	-15	-15	N/A
6/30/2022	2	-13	-15	-15	N/A
3/31/2022	1	-13	-15	-15	N/A
12/31/2021	2	-14	-15	-15	N/A
9/30/2021	1	-14	-15	-15	N/A
6/30/2021	1	-12	-14	-14	N/A
3/31/2021	1	-10	-12	-12	N/A
12/31/2020	1	-9	-9	-9	N/A
9/30/2020	1	-9	-8	-8	N/A
6/30/2020	1	-9	-8	-8	N/A
3/31/2020	1	-8	-7	-7	N/A
12/31/2019	1	-8	-7	-7	N/A
9/30/2019	1	-6	-5	-5	N/A
6/30/2019	1	-5	-4	-4	N/A
3/31/2019	1	-5	-4	-4	N/A
12/31/2018	1	-4	-3	-3	N/A
9/30/2018	1	-4	-3	-3	N/A
6/30/2018	1	-4	-3	-3	N/A
3/31/2018	1	-4	N/A	-3	N/A
12/31/2017	1	-4	N/A	-3	N/A
9/30/2017	2	-3	N/A	-3	N/A
6/30/2017	2	-4	N/A	-3	N/A
3/31/2017	1	-5	N/A	-3	N/A
12/31/2016	2	-4	N/A	-3	N/A
9/30/2016	1	-4	N/A	-3	N/A
6/30/2016	1	-4	N/A	-3	N/A
3/31/2016	1	-3	N/A	-2	N/A
12/31/2015	1	-3	N/A	-2	N/A
9/30/2015	1	-2	N/A	-1	N/A
6/30/2015	1	-1	N/A	-1	N/A
3/31/2015	1	-1	N/A	-1	N/A
12/31/2014	2	-1	N/A	-1	N/A
9/30/2014	1	0	N/A	0	N/A
6/30/2014	1	0	N/A	0	N/A
3/31/2014	2	0	N/A	1	N/A
12/31/2013	2	0	N/A	1	N/A
9/30/2013	2	0	N/A	1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CYTH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CYTH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CYTH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CYTHDie Einnahmen des Unternehmens (66.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: CYTHDie Einnahmen des Unternehmens (66.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CYTH in 3 Jahren voraussichtlich hoch sein wird

Cyclo Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 12%

Consensus revenue estimates decrease by 29%, EPS upgraded

Consensus forecasts updated

Price target decreased to US$10.00

Consensus revenue estimates increase by 16%

Consensus forecasts updated

Recent updates

Cyclo Therapeutics, Inc. announced that it has received $3 million in funding from Rafael Holdings, Inc.

Rafael Holdings, Inc. (NYSE:RFL) entered into a definitive agreement to acquire unknown remaining stake of Cyclo Therapeutics, Inc. (NasdaqCM:CYTH).

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. announced that it has received $2 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1

Consensus EPS estimates fall by 12%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profitability

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1

Cyclo Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

CEO & Director exercised options to buy US$293k worth of stock.

Consensus revenue estimates decrease by 29%, EPS upgraded

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. Appoints Vivien Wong as Member of the Board

New major risk - Revenue size

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. announced that it has received $5 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc., Annual General Meeting, Jul 31, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Appoints William Conkling to Serve as Director

CEO & Director recently bought US$213k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Provides Clinical Program Update

Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics Commences Phase 2B Study of Trappsol Cyclo for the Treatment of Early Alzheimer’S Disease

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Price target decreased to US$10.00

Consensus revenue estimates increase by 16%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclo Therapeutics to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022

We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics, Inc. Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

Independent Vice Chairman recently bought US$53k worth of stock

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$0.94 loss in 3Q 2020)

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$1.60 loss in 2Q 2020)

Consensus forecasts updated

Cyclo Therapeutics, Inc. Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

Cyclo Therapeutics Provides Update on Trappsol® Cyclo

Cyclo therapeutics to join Russell 2000 Index

We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics Provides Business Update

First quarter 2021 earnings released: US$0.76 loss per share (vs US$2.18 loss in 1Q 2020)

Cyclo Therapeutics, Inc. Announces Design of Pivotal Phase 3 Study Evaluating Trappsol Cyclo in Niemann-Pick Type C1

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Independent Chairman recently bought US$81k worth of stock

Full year 2020 earnings released: US$5.59 loss per share (vs US$6.96 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Cyclo Therapeutics, Inc. Appoints Russ Belden as Acting Chief Commercial Officer

Cyclo Therapeutics, Inc. Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on Agreement of Paediatric Investigation Plan for Trappsol® Cyclo™

Cyclo Therapeutics, Inc. Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer

Gewinn- und Umsatzwachstumsprognosen